滚动资讯
FierceBiotechViridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincingFierceBiotechKevin Tang uses newfound control of Aurinia to finally take over KezarFierceBiotechBoston Scientific’s Watchman heart implant measures up to blood thinners in ACC trialFierceBiotechMerck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivalsEndpoints NewsViridian’s autoimmune eye disease shot passes Phase 3, but can it compete?Endpoints NewsBlackstone raises $6.3B life sciences fund in record fundraising haulEndpoints NewsTakeda cuts 600+ US jobs; United's stock rises on Tyvaso dataBioWorldBiggest gainers and losers for March 23-27, 2026Endpoints News#ACC26: Kardigan's repeat dosing of blood pressure drug has no benefit over single shotBioPharma DiveObesity drugmaker Kailera plans an IPOPromega BlogWhen Cancer Research Depends on Quality RNA: Maxwell® RSC in the LabEndpoints NewsEli Lilly to pay $115M upfront to Insilico in AI drug discovery deal
Endpoints News 2026年3月30日

Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?

Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?

原文
暂时没有全文，请查看原始来源。

目录

59 全部